Glenmark Pharma aims for zero debt by March 2026
pre-market1 source ↓written by the desknot a recommendation
- in capital expenditures
- ₹800 cr
- currently
- 110 days
Glenmark Pharmaceuticals has set a target to eliminate gross debt by March 2026 while planning ₹800 cr in capital expenditures. The company aims to optimize its net working capital cycle, currently at 110 days, to enhance operational efficiency. This strategic move may improve investor sentiment and strengthen its financial position.
Not investment advice. For informational purposes only.